Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dengue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Dengue. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2014-001711-40 Sponsor Protocol Number: CYD24 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004501-30 Sponsor Protocol Number: V181-003 Start Date*: 2022-06-14
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [live, attenuated]) ...
    Medical condition: Prevention of dengue disease in toddlers, children, and adults in endemic areas, as well as travelers to endemic areas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10012309 Dengue LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-001710-25 Sponsor Protocol Number: CYD23 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001709-41 Sponsor Protocol Number: CYD22 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000027-36 Sponsor Protocol Number: DEN-303 Start Date*: 2023-02-03
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Are...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003136-23 Sponsor Protocol Number: CYD66 Start Date*: 2020-02-12
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001706-17 Sponsor Protocol Number: CYD06 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in Mexico
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002854-25 Sponsor Protocol Number: CYD65 Start Date*: 2020-09-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years after the L...
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001717-11 Sponsor Protocol Number: CYD32 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003135-36 Sponsor Protocol Number: CYD67 Start Date*: 2019-10-31
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003980-77 Sponsor Protocol Number: DEN-315 Start Date*: 2018-12-13
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adoles...
    Medical condition: The purpose of this study is to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001736-11 Sponsor Protocol Number: CYD33 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015588-15 Sponsor Protocol Number: IC51-323 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 12:29:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA